Literature DB >> 2351781

Acute myocardiotoxicity during 5-fluorouracil therapy.

B Misset1, B Escudier, B Leclercq, D Rivara, P Rougier, G Nitenberg.   

Abstract

A 38-year-old man with a colonic carcinoma experienced cardiogenic shock during continuous intravenous treatment with 5-fluorouracil (5-FU), without clinical or electrical signs of coronary insufficiency and with a normal coronary angiogram. His symptoms resolved after eight days of inotropic and vasodilator therapy. Because of the severity of the shock, rechallenge was not performed. This is the first case of acute cardiac failure without coronary ischemia, associated with 5-FU monotherapy. Experimental studies suggest that this adverse effect could be due to myocardial accumulation of 5-FU leading to depletion of high energy phosphate compounds. This might also explain the more frequently seen acute coronary insufficiency due to 5-FU.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351781     DOI: 10.1007/bf01724805

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  Myocardiotoxicity of 5 fluorouracil.

Authors:  B Coronel; O Madonna; A Mercatello; A Caillette; J F Moskovtchenko
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Correlation of 5-fluorouracil (NSC-19893) distribution in rodents with toxicity and chemotherapy in man.

Authors:  R H Liss; M Chadwick
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

3.  [Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluorouracil].

Authors:  R Levillain
Journal:  C R Seances Soc Biol Fil       Date:  1972-11-09

4.  Cardiotoxic effects of 5-fluorouracil in the guinea pig.

Authors:  I Matsubara; J Kamiya; S Imai
Journal:  Jpn J Pharmacol       Date:  1980-12

5.  The cardiotoxicity of anticancer agents.

Authors:  D D Von Hoff; M Rozencweig; M Piccart
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

6.  Prinzmetal's angina during 5-fluorouracil chemotherapy.

Authors:  N S Kleiman; D E Lehane; C E Geyer; C M Pratt; J B Young
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

7.  Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.

Authors:  A A Jakubowski; N Kemeny
Journal:  Cancer       Date:  1988-07-15       Impact factor: 6.860

8.  [Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management].

Authors:  B Escudier; J B Alexandre; B Leclercq; P Morin; J M Guyot; G Nitenberg
Journal:  Presse Med       Date:  1986-10-18       Impact factor: 1.228

9.  Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.

Authors:  R Labianca; G Beretta; M Clerici; P Fraschini; G Luporini
Journal:  Tumori       Date:  1982-12-31
  9 in total
  3 in total

1.  Thrombophilia, left ventricular dysfunction and intracardiac thrombi in children.

Authors:  Ibrahim Abu-Kishk; Shaul Baram; Eran Kozer; Baruch Klin; Gideon Eshel
Journal:  Korean Circ J       Date:  2011-08-31       Impact factor: 3.243

Review 2.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

3.  Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes.

Authors:  Chiara Focaccetti; Antonino Bruno; Elena Magnani; Desirée Bartolini; Elisa Principi; Katiuscia Dallaglio; Eraldo O Bucci; Giovanna Finzi; Fausto Sessa; Douglas M Noonan; Adriana Albini
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.